Barinthus Biotherapeutics PLC Sponsored ADR (BRNS)
(Delayed Data from NSDQ)
$2.30 USD
+0.15 (6.91%)
Updated May 22, 2024 03:57 PM ET
After-Market: $2.26 -0.04 (-1.74%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BRNS 2.30 +0.15(6.91%)
Will BRNS be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for BRNS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BRNS
Synlogic, Inc. (SYBX) Reports Q4 Loss, Tops Revenue Estimates
Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates
BRNS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Top Estimates
The Joint Corp. (JYNT) Q4 Earnings and Revenues Top Estimates
Other News for BRNS
Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024
Barinthus Biotherapeutics to present VTP-300 data updates at EASL Congress 2024
Barinthus price target lowered to $11 from $12 at Alliance Global Partners
Buy Rating for Barinthus Biotherapeutics Backed by Strong Financials and Promising Clinical Trials
Analysts Offer Insights on Healthcare Companies: Barinthus Biotherapeutics (BRNS) and GoodRx Holdings (GDRX)